SOAT1 and acute lymphoblastic leukemia: Additionally, in the total therapy XVII study (NCT03117751), patients with Ph-like ALL with JAK-STAT signaling activation and with day 15 or day 22 MRD ≥ 5% and all the patients with ETP and MPAL received combination therapy with ruxolitinib.